// App-Quantinova.ai

: Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study

Researchers

Presenter

  • Proton Rahman

Principal Investigators

  • Alice B. Gottlieb

  • Elizabeth Hsia

  • Alexa Kollmeier

  • Xie Xu

  • Ramanand Subramanian

  • Prasheen Agarwal

  • Shihong Sheng

  • Bei Zhou

  • Desiree van der Heijde

  • Iain McInnes

Medical Centers

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

  • Memorial University of Newfoundland, Newfoundland and Labrador, Canada.

  • Icahn School of Medicine at Mt Sinai, NY, NY, New York, New York

  • Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA

  • Janssen Research & Development, LLC, Spring House, Pennsylvania, United States

  • Janssen Research and Development, LLC, Spring House, PA

  • Leiden University Medical Centre, Leiden, Netherlands

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

Locations

  • United States

  • Canada

  • Netherlands

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Interleukin

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved